1. Home
  2. EOSE vs TYRA Comparison

EOSE vs TYRA Comparison

Compare EOSE & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eos Energy Enterprises Inc.

EOSE

Eos Energy Enterprises Inc.

HOLD

Current Price

$1.85

Market Cap

1.4B

Sector

Miscellaneous

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$18.55

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOSE
TYRA
Founded
2008
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
EOSE
TYRA
Price
$1.85
$18.55
Analyst Decision
Buy
Strong Buy
Analyst Count
11
15
Target Price
$6.50
★ $47.45
AVG Volume (30 Days)
★ 25.7M
725.2K
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $114,203,000.00
N/A
Revenue This Year
$166.51
N/A
Revenue Next Year
$89.11
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 631.79
N/A
52 Week Low
$1.85
$13.35
52 Week High
$19.86
$40.65

Technical Indicators

Market Signals
Indicator
EOSE
TYRA
Relative Strength Index (RSI) 26.27 31.90
Support Level N/A N/A
Resistance Level $4.45 $27.00
Average True Range (ATR) 0.21 0.89
MACD -0.12 -0.10
Stochastic Oscillator 1.67 5.38

Price Performance

Historical Comparison
EOSE
TYRA

About EOSE Eos Energy Enterprises Inc.

Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: